» Articles » PMID: 11925436

BARD1 Induces BRCA1 Intranuclear Foci Formation by Increasing RING-dependent BRCA1 Nuclear Import and Inhibiting BRCA1 Nuclear Export

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Apr 2
PMID 11925436
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

BRCA1 is a tumor suppressor with several important nuclear functions. BRCA1 has no known cytoplasmic functions. We show here that the two previously identified nuclear localization signals (NLSs) are insufficient for nuclear localization of BRCA1 due to the opposing action of an NH2-terminal nuclear export signal. In transfected breast cancer cells, BRCA1 nuclear localization requires both the NLSs and NH2-terminal RING domain region; mutating either of these sequences shifts BRCA1 to the cytoplasm. The BRCA1 RING element mediates nuclear import via association with BARD1, and this is not affected by cancer-associated RING mutations. Moreover, BARD1 directly masks the BRCA1 nuclear export signal, and the resulting block to nuclear export is requisite for efficient import and nuclear localization of ectopic and endogenous BRCA1. Our results explain why BRCA1 exon 11 splice variants, which lack the NLSs but retain the RING domain, are frequently detected in the nucleus and in nuclear foci in vivo. In fact, co-expression of BARD1 promoted formation of DNA damage-induced nuclear foci comprising ectopic wild-type or NLS-deficient BRCA1, implicating BARD1 in nuclear targeting of BRCA1 for DNA repair. Our identification of BARD1 as a BRCA1 nuclear chaperone has regulatory implications for its reported effects on BRCA1 protein stability, ubiquitin ligase activity, and DNA repair.

Citing Articles

Functional Characterization of the Human BRCA1 ∆11 Splicing Isoforms in Yeast.

Galli A, Belle F, Fargnoli A, Caligo M, Cervelli T Int J Mol Sci. 2024; 25(14).

PMID: 39062754 PMC: 11276823. DOI: 10.3390/ijms25147511.


Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L Mol Cancer. 2024; 23(1):88.

PMID: 38702734 PMC: 11067278. DOI: 10.1186/s12943-024-02005-y.


Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant.

Block I, Mateu-Regue A, Do T, Miceikaite I, Sdogati D, Larsen M Breast Cancer Res. 2024; 26(1):6.

PMID: 38195559 PMC: 10775606. DOI: 10.1186/s13058-023-01755-9.


Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.

Zhao S, Wang Q, Ni K, Zhang P, Liu Y, Xie J Front Immunol. 2023; 14:1263329.

PMID: 37727789 PMC: 10505933. DOI: 10.3389/fimmu.2023.1263329.


Targeted splicing therapy: new strategies for colorectal cancer.

Zheng Y, Zhong G, He C, Li M Front Oncol. 2023; 13:1222932.

PMID: 37664052 PMC: 10470845. DOI: 10.3389/fonc.2023.1222932.